The Health Insurance Review and Assessment Service is expected to require the oral SMA (spinal muscular atrophy) treatment ‘Evrysdi Dry Syrup (risdiplam, Roche)’ to receive prior authorization for reimbursement.

Also, HIRA is planning to reflect the prior authorization experience it has accumulated from Spinraza for Evrysdi.

HIRA’s Healthcare Review and Assessment Committee announced so at a special press corps meeting with industry reporters on the 18th.

Jin-Su Lee, Chair of the Healthcare Review and Assessment Committee, said, ”After literature review and reflection of overseas cases, we have prepared an announcement on the revised measures for prior authoriza